Full Title
Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma (SaLuDo)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Sujana Movva’s office at 646-888-6787.
Protocol
25-030
Phase
Phase III (phase 3)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06088290